PH12019550096A1 - Beta-casein a2 and prevention of inflammation of the bowel - Google Patents

Beta-casein a2 and prevention of inflammation of the bowel

Info

Publication number
PH12019550096A1
PH12019550096A1 PH12019550096A PH12019550096A PH12019550096A1 PH 12019550096 A1 PH12019550096 A1 PH 12019550096A1 PH 12019550096 A PH12019550096 A PH 12019550096A PH 12019550096 A PH12019550096 A PH 12019550096A PH 12019550096 A1 PH12019550096 A1 PH 12019550096A1
Authority
PH
Philippines
Prior art keywords
casein
beta
bowel
inflammation
prevention
Prior art date
Application number
PH12019550096A
Inventor
Malav Suchin Trivedi
Andrew John Clarke
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019550096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of PH12019550096A1 publication Critical patent/PH12019550096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The use of a composition for preventing or reducing the risk of inflammation of the bowel in an animal, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 50 pcnt by weight beta-casein A2.
PH12019550096A 2013-05-31 2019-06-13 Beta-casein a2 and prevention of inflammation of the bowel PH12019550096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829764P 2013-05-31 2013-05-31
PCT/NZ2014/000102 WO2014193248A1 (en) 2013-05-31 2014-05-30 Beta-casein a2 and prevention of inflammation of the bowel

Publications (1)

Publication Number Publication Date
PH12019550096A1 true PH12019550096A1 (en) 2020-02-10

Family

ID=51989162

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12015502674A PH12015502674B1 (en) 2013-05-31 2015-11-27 Beta-casein a2 and prevention of inflammation of the bowel
PH12019550096A PH12019550096A1 (en) 2013-05-31 2019-06-13 Beta-casein a2 and prevention of inflammation of the bowel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PH12015502674A PH12015502674B1 (en) 2013-05-31 2015-11-27 Beta-casein a2 and prevention of inflammation of the bowel

Country Status (20)

Country Link
US (2) US20160113997A1 (en)
EP (2) EP3542813A1 (en)
JP (2) JP6867158B2 (en)
KR (2) KR102402455B1 (en)
CN (2) CN112316116A (en)
AU (2) AU2014271423B2 (en)
BR (1) BR112015029987A8 (en)
CA (1) CA2913890A1 (en)
CL (1) CL2015003507A1 (en)
DK (1) DK3003485T3 (en)
ES (1) ES2742306T3 (en)
HK (1) HK1222362A1 (en)
IL (2) IL242833B (en)
MX (2) MX367794B (en)
MY (1) MY179497A (en)
PH (2) PH12015502674B1 (en)
RU (1) RU2669553C2 (en)
SG (2) SG11201509769QA (en)
WO (1) WO2014193248A1 (en)
ZA (1) ZA201508983B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102402455B1 (en) * 2013-05-31 2022-05-25 디 에이2 밀크 컴퍼니 리미티드 Beta-casein a2 and prevention of inflammation of the bowel
GB2519101A (en) * 2013-10-09 2015-04-15 Nicoventures Holdings Ltd Electronic vapour provision system
WO2015187795A1 (en) * 2014-06-03 2015-12-10 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient
CN107708711A (en) * 2015-05-22 2018-02-16 艾尔牛奶有限公司 β caseins A2 and oxidation resistance
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function
KR20220040497A (en) * 2016-09-30 2022-03-30 디 에이2 밀크 컴퍼니 리미티드 Beta-caseins and gut microbiota
CN109563049B (en) * 2016-10-14 2022-11-29 豪夫迈·罗氏有限公司 Imidazole compounds as EAAT3 inhibitors
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
CN112205476A (en) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 Beta-casein A2 and application of composition thereof in promoting proliferation of bifidobacterium
WO2021003741A1 (en) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 APPLICATION OF β-CASEIN A2 AND COMPOSITION THEREOF IN PROMOTING PROLIFERATION OF BIFIDOBACTERIUM
CN115708530A (en) * 2022-11-15 2023-02-24 北大荒完达山乳业股份有限公司 Pregnant and lying-in woman formula milk powder capable of promoting digestive comfort and stabilizing blood sugar and preparation method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789842B1 (en) 1994-11-04 2009-09-09 A2 Corporation Limited Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
US6570060B2 (en) 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
NZ306584A (en) * 1995-05-16 2000-02-28 Corran Norman Stuart Mclachlan Milk or dairy products derived from animals and which are free of beta casein
AU4266100A (en) * 1995-05-16 2000-10-12 Corran Norman Stuart Mclachlan Food product and process
CN1159984C (en) * 1999-06-29 2004-08-04 新西兰奶制品研究所有限公司 Prophylactic dietary supplement based on milk
NZ516712A (en) * 1999-06-29 2003-10-31 New Zealand Milk Inst Ltd Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
WO2002083164A2 (en) * 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
US7481127B2 (en) 2004-09-27 2009-01-27 Lester William T Continuously variable transmission using oscillating torque and one-way drives
IES20070714A2 (en) * 2006-10-06 2008-04-16 Kerry Group Services Int Ltd A milk protein composition and use thereof
US8871276B2 (en) * 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
TWI516269B (en) * 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
KR102402455B1 (en) * 2013-05-31 2022-05-25 디 에이2 밀크 컴퍼니 리미티드 Beta-casein a2 and prevention of inflammation of the bowel

Also Published As

Publication number Publication date
US20200179485A1 (en) 2020-06-11
US11911439B2 (en) 2024-02-27
HK1222362A1 (en) 2017-06-30
CA2913890A1 (en) 2014-12-04
MX2015016493A (en) 2016-08-18
CN105407971B (en) 2020-11-17
ZA201508983B (en) 2017-11-29
RU2018131733A (en) 2018-11-08
JP2016520611A (en) 2016-07-14
MX2019010594A (en) 2019-10-15
AU2018274937A1 (en) 2019-01-03
EP3003485A4 (en) 2016-11-30
MX367794B (en) 2019-09-06
IL262302B (en) 2021-02-28
BR112015029987A2 (en) 2017-07-25
SG11201509769QA (en) 2015-12-30
ES2742306T3 (en) 2020-02-13
KR20160024884A (en) 2016-03-07
AU2018274937B2 (en) 2020-10-29
SG10201709509RA (en) 2017-12-28
IL262302A (en) 2018-11-29
BR112015029987A8 (en) 2021-12-07
PH12015502674A1 (en) 2016-03-07
JP7224242B2 (en) 2023-02-17
AU2014271423A1 (en) 2015-12-24
JP2019165746A (en) 2019-10-03
NZ714912A (en) 2021-06-25
RU2018131733A3 (en) 2021-10-29
DK3003485T3 (en) 2019-08-19
MY179497A (en) 2020-11-09
AU2014271423B2 (en) 2018-12-20
KR102282972B1 (en) 2021-07-28
JP6867158B2 (en) 2021-04-28
CL2015003507A1 (en) 2016-12-16
CN112316116A (en) 2021-02-05
US20160113997A1 (en) 2016-04-28
WO2014193248A1 (en) 2014-12-04
RU2015153113A (en) 2017-07-05
EP3003485B1 (en) 2019-05-15
PH12015502674B1 (en) 2016-03-07
KR20210094674A (en) 2021-07-29
IL242833B (en) 2019-07-31
CN105407971A (en) 2016-03-16
EP3542813A1 (en) 2019-09-25
RU2669553C2 (en) 2018-10-12
KR102402455B1 (en) 2022-05-25
EP3003485A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
PH12019550096A1 (en) Beta-casein a2 and prevention of inflammation of the bowel
HUE051950T2 (en) Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
MX2020006595A (en) Fungicidal oxadiazoles.
HK1254654A1 (en) 4,6-pyrimidinylene derivatives and uses thereof
EP3010892B8 (en) 1,2,4-triazoles as nuclear transport modulators and uses thereof
IL256455B (en) Phenoxyhalogenphenylamidines and the use thereof as fungicides
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2019009842A (en) Solid composition comprising amorphous sofosbuvir.
GB2525098B (en) Equipment for use when sitting and when walking, skiing or the like
EP2958926A4 (en) Epidithiodioxopiperazine compound or its derivatives, and the use thereof
GB2519982B (en) Fungicidal composition and the use thereof
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
IL248271A0 (en) Dietary compositions for reducing blood glucose levels and for weight management
PL3359676T3 (en) Transposon system, kit comprising the same, and uses thereof
EP3187178A4 (en) Composition for reducing local fat and body weight, and pharmaceuticals and use thereof
PH12020550185A1 (en) Semaglutide in medical therapy
EP3175723A4 (en) Men's underwear
PH12017500084A1 (en) Vitamin b2 and its use
EP3227293A4 (en) 6.7-cyclicmorphinan derivatives and use thereof
MX2019013642A (en) Compounds, compositions and methods.
Mighton For the love of math
AU355724S (en) Tensioner bracket
Khedun The right to remain silent: an unfair advantage.
Lindstrom Lumber Landings, Doghole Schooners and Shipwrecks